Literature DB >> 1380408

In vivo effects of doxorubicin on kinase C in cultured cells.

M Otsuka1, H Shigeoka, H C Yang.   

Abstract

The ability of doxorubicin to inhibit kinase C in vivo in cultured BALB/c 3T3 mouse fibroblasts was determined by the phosphorylation of the myristoylated alanine-rich C kinase substrate (MARCKS) and the induction of c-fos transcription following treatment with 200 nM phorbol 12-myristate 13-acetate. A concentration of 60 microM doxorubicin did not inhibit MARCKS phosphorylation but completely inhibited c-fos expression. The inhibition of c-fos expression was not specifically mediated via kinase C, since both the total RNA synthesis as measured by [3H]-uridine uptake and the fraction of serum-induced c-fos expression that was not attributable to kinase C were inhibited by doxorubicin. The present data do not support the hypothesis that the cytotoxic effect of doxorubicin is attributable to the inhibition of kinase C in vivo.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1380408     DOI: 10.1007/bf00689970

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  31 in total

1.  Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I.

Authors:  P W Rigby; M Dieckmann; C Rhodes; P Berg
Journal:  J Mol Biol       Date:  1977-06-15       Impact factor: 5.469

2.  Inhibition of DNA and RNA metabolism by daunorubicin and adriamycin in L1210 mouse leukemia.

Authors:  W D Meriwether; N R Bachur
Journal:  Cancer Res       Date:  1972-06       Impact factor: 12.701

3.  Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose.

Authors:  P S Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

4.  Adriamycin interacts with diacylglycerol to inhibit human leukemia protein kinase C.

Authors:  F K Zhao; L F Chuang; M Israel; R Y Chuang
Journal:  Anticancer Res       Date:  1989 Jan-Feb       Impact factor: 2.480

5.  Level of protein kinase C activity correlates directly with resistance to adriamycin in murine fibrosarcoma cells.

Authors:  C A O'Brian; D Fan; N E Ward; C Seid; I J Fidler
Journal:  FEBS Lett       Date:  1989-03-27       Impact factor: 4.124

6.  Disappearance of Ca2+-sensitive, phospholipid-dependent protein kinase activity in phorbol ester-treated 3T3 cells.

Authors:  A Rodriguez-Pena; E Rozengurt
Journal:  Biochem Biophys Res Commun       Date:  1984-05-16       Impact factor: 3.575

7.  Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols.

Authors:  R F Greene; J M Collins; J F Jenkins; J L Speyer; C E Myers
Journal:  Cancer Res       Date:  1983-07       Impact factor: 12.701

8.  The role of membranes in the mechanism of action of the antineoplastic agent adriamycin. Spin-labeling studies with chronically hypoxic and drug-resistant tumor cells.

Authors:  J A Siegfried; K A Kennedy; A C Sartorelli; T R Tritton
Journal:  J Biol Chem       Date:  1983-01-10       Impact factor: 5.157

9.  Phorbol esters induce multidrug resistance in human breast cancer cells.

Authors:  R L Fine; J Patel; B A Chabner
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

10.  Adriamycin-induced changes in the surface membrane of sarcoma 180 ascites cells.

Authors:  S A Murphree; T R Tritton; P L Smith; A C Sartorelli
Journal:  Biochim Biophys Acta       Date:  1981-12-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.